论文部分内容阅读
目的：探讨子宫内膜癌多药耐药（ｍｕｌｔｉｄｒｕｇｒｅｓｉｓｔａｎｃｅ１，ＭＤＲ１）基因１产物Ｐ糖蛋白（Ｐｇｐ）表达与子宫内膜癌ＭＤＲ的关系。方法：用ＳＰ免疫组化法测定４０例子宫内膜癌，１０例子宫内膜增殖症和１０例正常子宫内膜组织Ｐｇｐ表达，并与ＰＲ受体、细胞分级和临床分期等预后因素进行相关分析。结果：（１）上述所有组织均有Ｐｇｐ表达，其中子宫内膜癌Ｐｇｐ强阳性表达率较正常子宫内膜组织高，差异有显著性；与子宫内膜增殖症比较，二者差异无显著性。（２）Ｐｇｐ强阳性表达与子宫内膜癌临床分期、组织病理类型、ＰＲ受体以及５年生存率无关；与细胞分级有关，低分化内膜癌Ｐｇｐ强阳性较中、高分化内膜癌Ｐｇｐ强阳性表达高，二者差异有统计学意义。结论：子宫内膜癌患者对抗肿瘤药具有先天性抗药性，Ｐｇｐ表达是子宫内膜癌化疗疗效不佳的原因之一。
Objective: To investigate the relationship between the expression of P-glycoprotein (P-gp), a product of multidrug resistance 1 (MDR1) gene and MDR in endometrial carcinoma. Methods: The expression of Pgp in 40 cases of endometrial carcinoma, 10 cases of endometrial hyperplasia and 10 cases of normal endometrial tissue were detected by SP immunohistochemical method. The expressions of Pgp, PR receptor, cell stage, clinical stage and other prognostic factors Related analysis. Results: (1) All of the above tissues had P-gp expression, in which the strong positive expression rate of P-gp in endometrial carcinoma was higher than that in normal endometrial tissue, the difference was significant; compared with endometrial hyperplasia, both No significant difference. (2) P-gp strongly positive expression of endometrial cancer clinical stage, histopathological type, PR receptor and 5-year survival rate unrelated; and cell classification, poorly differentiated endometrial cancer P gp strong positive than the high Differentiated endometrial cancer P gp strong positive expression, the difference was statistically significant. Conclusion: Endometrial cancer patients with congenital resistance to anticancer drugs, P gp expression is one of the reasons for poor response to endometrial cancer chemotherapy.